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Abstract. In endemic settings, health facility surveys provide a convenient approach to estimating malaria transmission
intensity. Typically, testing for malaria at facilities is performed on symptomatic attendees, but asymptomatic infections
comprise a considerable proportion of the parasite reservoir. We sampled individuals attending five health facilities in the
western Kenyan highlands. Malaria prevalence by rapid diagnostic test (RDT) was 8.6–32.9% in the health facilities. Of all
polymerase chain reaction-positive participants, 46.4% (95% confidence interval [95% CI] = 42.6–50.2%) of participants
had infections that were RDT-negative and asymptomatic, and 55.9% of those infections consisted of multiple parasite
clones as assessed by merozoite surface protein-2 genotyping. Subpatent infections were more common in individuals
reporting the use of non-artemisinin–based antimalarials in the 2 weeks preceding the survey (odds ratio = 2.49, 95%
CI = 1.04–5.92) compared with individuals not reporting previous use of antimalarials. We observed a large and genetically
complex pool of subpatent parasitemia in the Kenya highlands that must be considered in malaria interventions.
INTRODUCTION
To allow national programs to effectively tailor malaria
control strategies to local transmission dynamics, it is essential
that existing surveillance systems are capable of providing
accurate, spatially specific measures of malaria transmission
intensity.1,2 Most malaria surveillance systems, including the
system in Kenya, are predicated on passive detection of cases
at health facilities using either clinical diagnosis alone or clin-
ical diagnosis with parasitological confirmation by microscopy
or rapid diagnostic tests (RDTs).3–6 However, estimates of
malaria burden from passive case detection data are subject
to a number of potential biases that can vary considerably
between health facilities, including the occurrence of non-
malarial fevers, variations in accessibility of health services,
willingness to pay any ancillary costs, and diagnostic test used.
In addition, the experience of the laboratory and clinical per-
sonnel, quality of microscopy, particular brand or availability
of RDTs, and time dedicated to malaria testing are also
important potential sources of bias, making results difficult
to compare.6,7
Health facility-based cross-sectional surveys that sample
from all individuals presenting at the facility as well as any
accompanying individuals (as distinct from sampling only
among individuals with suspected malaria) have been shown
to be a useful tool for measuring malaria transmission inten-
sity.8,9 Health facility surveys provide an operationally attrac-
tive method to estimate malaria prevalence in the wider
catchment population, because the inclusion of all health
facility attendees mitigates against some of the biases associ-
ated with passive case detection.7,10 However, most health
facility malaria surveys have relied on diagnosis by micros-
copy or RDT, both of which have a limited ability to detect
parasitemia at low parasite densities.8,11,12 The number of
malaria infections detected through these surveys is, there-
fore, likely to have been substantially lower than would have
been achieved using a more sensitive diagnostic approach,
such as polymerase chain reaction (PCR).11,13,14 The poten-
tially large proportion of infections that is undetected poses a
significant challenge for malaria surveillance, control, and
elimination strategies: transmission is likely underestimated,
and reservoirs of infection missed. As a result, control pro-
grams may only target a subset of the actual parasite popula-
tion, or campaigns may be implemented before the parasite
reservoir is at or below the threshold where elimination is
feasible.13,15–17
In this study, two cross-sectional surveys were carried out in
five rural health facilities in the highlands of western Kenya to
(1) assess the use of this type of survey approach for measur-
ing malaria transmission, (2) identify the prevalence and
complexity of asymptomatic and subpatent infections, and
(3) evaluate factors associated with having asymptomatic
and subpatent infections.
METHODS
Study site and population. This study was conducted in
health facilities in a highland fringe area covering a region
of approximately 200 km2 in Rachuonyo South, Nyanza Prov-
ince in the western Kenyan highlands. The area is situated
between 1,400 and 1,600 m above sea level, and the landscape
is characterized by rolling terrain intersected with rivers and
streams. The population is predominantly people from the
Luo ethnic group, with subsistence farming being the main
occupation.18 Malaria in the area is spatially heterogeneous,
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with prevalence estimates in primary schools ranging between
0% and 71%, and transmission follows a bimodal seasonal
pattern associated with the long and short rainy seasons typi-
cally occurring between April and June and between October
and December, respectively.19,20 The predominant malaria
vectors in the area are Anopheles funestus and An. arabiensis,
and Plasmodium falciparum is the principal malaria parasite
species present.21 Two surveys were conducted in five rural
health facilities representing all government facilities in the
area in collaboration with the District Ministry of Health.
Sampling took place in Agawo, Ober, Omiro, and Tala health
facilities in both surveys. In the second survey, Othoro Health
Center was replaced with Wire Dispensary, a faith-based
facility, to achieve maximum overlap with the ongoing com-
munity work (Figure 1). The surveys were conducted in Octo-
ber of 2011 and July of 2012 to correspond with periods of low
and high transmission, respectively, and we examine the sen-
sitivity of these surveys to changes in transmission intensity.18
Consenting and sample collection. All consenting patients
and those accompanying them who attended the outpatient
department during the 4-week survey period were eligible for
inclusion. At each facility, maximums of 150 people from each
of three age categories (0.5–5, 6–15, and > 15 years old) were
included. Recruitment within an age category was stopped
after the target had been reached. Individuals were excluded
if they were extremely ill and required immediate medical
attention, were < 6 months of age, were attending a scheduled
clinic or other ward of the health facility, were unwilling or
unable to provide consent (e.g., under 18 years old without
being accompanied by a suitable guardian), or had been pre-
viously sampled at that same facility during this study.
Two field workers were stationed at each facility, and data
collection activities were integrated into the normal day-to-day
operations as far as possible. A field worker would approach
each potential eligible participant and explain the study while
he/she was waiting to visit the clinician. After the consenting
process, a short questionnaire was administered on participant
demographics, malaria history, control behaviors, whether
he/she was a patient or accompanying person, current and
recent symptoms, recent drug use, and travel history. Each
participant was screened by RDT to determine the presence of
current patent infections; three blood spots were collected on
filter paper (3MM Whatman, Maidstone, United Kingdom)
for subsequent molecular and serological analysis. Filter papers
were dried and stored with desiccant at −80 °C. In the first year
of the survey, axillary temperature was measured using a digital
thermometer, and those with temperature > 37.2°C were con-
sidered febrile.18 In the second year, tympanic thermometers
were used because of the increased accuracy and shorter time
to result. For those tested with the tympanic thermometers,
only those with temperatures > 37.5 °C were considered febrile.
In the second survey, the RDT was changed from Paracheck
(Orchid Biomedical Systems, Goa, India) to the more sensitive
First Response Kit (Premier Medical Corporation Ltd., Nani
Daman, India).22 All diagnostic information was made avail-
able to the clinician for clinical decision-making. The final diag-
nosis and any drugs prescribed by the clinician to study
participants were also recorded.
Research ethics. The ethical committees of the London
School of Hygiene and Tropical Medicine (LSHTM 5956) and
the Kenya Medical Research Institute (SSC 1589) approved
this study. Individual informed consent was obtained from
all participants by signature or thumbprint accompanied by
the signature of an independent witness. Consent for chil-
dren under the age of 18 years old was provided by a parent/
guardian, and children between 14 and 17 years old also pro-
vided written assent by signature or thumbprint accompanied
by the signature of an independent witness. As defined in the
Figure 1. Health facility survey study area. Locations of rural health facilities included in the study as well as government primary schools and
boundaries of the community survey. Note that Othoro Health Center is located along the main road approximately 20 km to the west of this area.
1102 STRESMAN AND OTHERS
Kenya national guidelines, participants below 18 years of age
who were pregnant, married, or had a child were considered
mature minors and consented for themselves.23
Laboratory analysis. Filter paper blood spots were used
to test for antibodies to malaria to ascertain malaria exposure
and transmission intensity. Antibodies to P. falciparum
Apical Membrane Antigen-1 (AMA1) and Merozoite Surface
Protein-1 (MSP1-19) were detected by enzyme-linked immu-
nosorbent assay (ELISA). Briefly, two blood spot sections per
sample were punched, and antibodies were eluted according
to work by Baidjoe and others.24 Antibody prevalence for
each antigen was determined after defining a cutoff optical
density (OD) based on a standard curve of known antibody
concentration using the mixture model and normalized across
plates.20,25 A person was considered to be seropositive if they
had normalized OD values above the cutoff for at least one
of the antigens tested. Age-adjusted seroconversion rates
(SCRs) were calculated.25
Nested PCR (nPCR) was used to test for the presence of
parasite DNA to provide a gold standard measure for current
infection. A Chelex-saponin approach was used to extract
DNA as described by Baidjoe and others,24 and the nPCR
assay targeting the 18S ribosomal subunit of P. falciparum
was used as previously described.26 Samples that were posi-
tive by nPCR were then selected for subsequent analysis to
identify allelic diversity using the polymorphic MSP2 region
to provide an alternate measure of transmission inten-
sity.24,25,27 An additional nPCR reaction was conducted to
amplify the block-3 region of the MSP2 domain targeting the
FC27 and IC3D7 allelic variants.28 The product of the MSP2
PCR was viewed on 1.5% agarose gel to determine the dilu-
tion factor necessary to prepare samples for capillary electro-
phoresis: intense bands were diluted at 1:100, moderate bands
were diluted at 1:40, and faint bands were diluted at 1:10.
Electropherograms were viewed using Peak Scanner (ver-
sion 1.0), and all discrete peaks > 500 florescent units were
considered to be distinct allelic types.29
Case definitions. Subpatent malaria infections were infec-
tions in individuals who tested positive for malaria by nPCR
but negative for malaria by RDT; patent infections were
defined as infections in individuals who were positive by both
nPCR and RDT. Individuals who were positive by RDT but
negative by PCR (N = 267) were considered to be false posi-
tives (likely attributable to residual HRP2 antigen) and not
included in the analysis exploring subpatent infections (how-
ever, they were included in estimates of RDT prevalence).30
Asymptomatic infections were infections in individuals who
tested positive for malaria by nPCR but were afebrile at the
time of sampling and did not report history of fever in the
24 hours before sampling.14
Statistical analysis. Statistical analysis was conducted using
Stata 12.1 (STATACorp LP) and R, version 3.02. Compari-
sons of parasite prevalence estimates between facilities,
between years, and between age categories were performed
using a two-sided test for proportions and the corresponding
exact binomial 95% confidence intervals (95% CIs). To assess
the ability of health facility surveys to provide reasonable
estimates of the community, data from a large community
cross-sectional survey conducted in July of 2011 in the same
study area were used.18 Data were restricted to those sampled
as part of the community survey who resided within the health
facility catchment areas as defined by cost–distance analysis,
and SCR was calculated as described above.31 The health
facility samples were restricted to those collected in July of
2012 to minimize any potential seasonal bias. Multiplicity of
infection (MOI) was calculated for all PCR positive samples,
and 95% CIs were calculated assuming a zero truncated
Poisson distribution to account for all samples containing a
minimum of one clone. Allelic richness (Rs), a metric for
allelic diversity, was calculated using FSTAT, version 2.9.3.2,
software as previously described.32
Random effects logistic regression was used to assess fac-
tors associated with having subpatent as well as asymptomatic
malaria infection. Explanatory variables tested included year,
sex, age, whether the individual was a patient or an accompa-
nying person, reported taking an antimalarial drug in the past
2 weeks, reported taking an antipyretic drug, reported using
a bed net the previous night, reported living in a household
where indoor residual spraying had taken place in the pre-
vious 6 months, and number of infecting parasite clones.
Because of the non-specificity of malaria symptoms, it was
not possible to further stratify patients by reason for attending
the facility. The final adjusted models were generated by
retaining all variables that were significant at the 0.05 level
in a backward fashion, and akaike information criteria (AIC)
values were used to confirm the optimum model fit.
RESULTS
Population demographics. In total, 1,598 and 1,444 people
were sampled in the first and second surveys, respectively,
and most were patients (Table 1). There were similar propor-
tions of males and females sampled in the < 5 and 6–15 years
age categories, but significantly more females than males
were sampled in the > 15 years age group (P < 0.0001). Most
of the accompanying people were > 15 years of age. Also, the
majority of individuals reported that they had slept under a
bed net the previous night, although in both surveys, partici-
pants ages 6–15 years were less likely to have reported using a
net than younger children (P < 0.0001) or adults (P < 0.0001)
(Table 1). The majority of patients (63.4%; 95% CI = 61.4–
65.3%; facility range [range] = 25.5–79.0%) reported having
a fever in the previous 24 hours compared with 19.0% of
accompanying people (95% CI = 15.9–22.4%; range = 0–
37.7%), but only 23.2% (95% CI = 21.5–24.9%; range =
18.4–37.0%) and 7.5% (95% CI = 5.4–9.7%; range = 0–
19.7%) of patients and accompanying people, respectively,
had a current fever at the time of their health visit. Overall,
30.6% (95% CI = 28.9–23.2%; range = 15.6–39.6%) of partic-
ipants reported having taken antipyretic drugs, and 13.7%
(95% CI = 12.5–15.0%; range = 8.8–21.9%) of participants
reported taking an antimalarial drug in the past 2 weeks.
Malaria transmission intensity. All metrics tested were able
to detect a change in malaria burden between the two surveys.
Seroprevalence estimates increased from 37.6% (95% CI =
35.2–40.0; range = 24.5–53.0%) during the first survey to
46.8% (95% CI = 44.2–49.4%; range = 34.4–62.0%) in the
second survey (P < 0.0001). Similarly, malaria parasite preva-
lence by RDT increased from 16.9% (95% CI = 15.1–18.8%;
range = 8.6–30.1%) to 22.4% (95% CI = 20.3–24.6%; range =
9.5–32.9%) and by PCR from 20.4% (95% CI= 18.4–22.4%;
range = 9.5–40.3%) to 25.5% (95% CI = 23.2–27.7%; range =
8.7–51.5%) during the first and second surveys, respectively
(Table 2). Prevalence within age categories also increased
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between surveys, with the highest estimates in the 6–15 years
age category and the lowest estimates in adults (P < 0.001)
(Supplemental Table 1).
Similarly, SCR indicated a range of transmission intensity
between facilities and an increase in transmission intensity
between the two surveys (Figure 2A). Also, based on this
small sample of five facilities, SCR estimates from the health
facility survey during the high-transmission season were
strongly correlated (r = 0.96) with estimates obtained from a
community cross-sectional survey in the same area conducted
the previous year (Figure 3). With the exception of allelic
diversity (P = 0.62), the malaria metrics tested were able to
consistently rank health facilities according to transmission
intensity, which was quantified by SCR. The intensity of
malaria transmission (indicated by SCR) experienced by indi-
viduals attending the selected health facilities during the first
survey was associated with health facility-level parasite prev-
alence by both RDT (P = 0.04) and PCR (P = 0.05) as well as
MOI (P = 0.04). Despite the association of RDT and trans-
mission intensity, it is worth noting that one facility (Agawo)
would have been misclassified as being in a high-transmission
setting based on RDT results in symptomatic patients alone
(Figure 2B). SCR during the first survey was also strongly
associated with SCR in the second survey (P < 0.001), and
ranks between transmission intensity and all malaria metrics
showed similar trends (data not shown).
Subpatent and asymptomatic infections. Overall, 586 infec-
tions were detected by RDT, and 54.4% of them were
confirmed by PCR. PCR identified an additional 358 infec-
tions (12.0% of the total study population). In total, 52.9%
Table 2
Prevalence of malaria per facility for all malaria metrics, including seroprevalence (Sero), and RDT prevalence, MOI, and Rs ordered from
highest to lowest transmission intensity
SCR 95% CI Sero (%) 95% CI PCR (%) 95% CI RDT (%) 95% CI MOI 95% CI Rs
Low-transmission season (October of 2011)
Tala 0.076 0.06–0.10 53.0 47.1–58.8 35.0 29.4–40.6 29.4 24.7–35.5 2.33 2.07–2.65 30.9
Omiro 0.069 0.05–0.09 49.1 43.1–55.0 40.3 34.4–46.1 16.9 13.7–23.2 1.99 1.79–2.24 24.1
Agawo 0.054 0.04–0.07 42.8 37.0–48.5 14.8 10.7–18.9 19.8 15.3–24.5 1.97 1.68–2.40 29.2
Ober 0.028 0.02–0.04 25.8 21.4–30.2 9.5 6.6–12.5 11.6 8.4–14.8 1.72 1.44–2.19 27.0
Othoro 0.025 0.02–0.03 24.5 19.9–29.0 9.5 6.4–12.6 8.6 5.7–11.6 1.84 1.56–2.28 29.0
High-transmission season (July of 2012)
Tala 0.114 0.09–0.14 62.1 56.3–67.7 51.6 45.8–57.3 32.9 27.4–38.3 2.29 2.09–2.52 37.1
Omiro 0.113 0.09–0.15 55.6 48.9–62.2 31.3 25.1–37.5 27.6 21.6–33.6 1.85 1.63–2.15 28.0
Wire 0.069 0.05–0.09 52.2 45.3–59.1 28.8 22.5–35.0 18.0 12.7–23.6 1.5 1.34–1.75 20.5
Agawo 0.061 0.05–0.07 39.5 34.2–44.5 16.2 12.4–20.1 27.1 22.4–31.7 2.12 1.84–2.50 39.5
Ober 0.048 0.04–0.06 34.2 29.4–39.0 8.7 5.8–11.5 9.5 6.6–12.5 1.95 1.60–2.53 18.0
Table 1
Demographics of the study population in health facility surveys in five rural health facilities carried out during the short and long malaria
transmission seasons
Low-transmission season (October of 2011) High-transmission season (July of 2012)
Mean 95% CI Range Mean 95% CI Range
N
All 1,598 − 284–388 1,444 − 203–379
6 months to 5 years 537 − 76–147 514 − 52–150
6–15 years 304 − 32–90 249 − 28–79
> 15 years 767 − 149–150 681 − 104–150
Sex (% male)
All 37.5 35.2–40.0 33.8–38.9 38.7 36.2–41.3 34.6–40.1
6 months to 5 years 49.0 44.7–53.3 43.7–53.9 52.3 47.9–56.7 44.4–58.0
6–15 years 47.0 41.3–52.8 42.9–54.2 46.6 40.3–53.0 39.7–54.4
> 15 years 25.6 22.5–28.9 20.6–31.8 25.5 22.3–29.0 22.4–31.5
Patient/accompanying status (% patient)
All 81.4 79.4–83.3 66.9–93.0 79.5 77.3–81.5 53.7–90.5
6 months to 5 years 96.5 94.5–97.8 91.6–91.7 93.8 91.3–95.7 88.5–98.0
6–15 years 96.0 93.2–97.9 90.6–100 97.2 94.3–98.9 92.9–100
> 15 years 64.9 61.4–68.3 43.9–85.3 62.3 58.5–65.9 30.4–80.8
Bed net (% reported sleeping under net previous night)
All 87.2 85.5–88.9 82.2–94.0 90.4 88.8–91.9 89.0–91.8
6 months to 5 years 86.8 83.6–89.6 82.6–92.1 94.0 91.5–95.9 88.7–97.5
6–15 years 82.1 77.3–86.3 69.6–92.3 81.1 75.7–85.8 76.0–84.8
> 15 years 89.6 87.2–91.7 84.1–96.7 91.2 88.8–93.2 89.6–93.3
Recent IRS (% reported having IRS in past 12 months)
All 77.8 75.4–80.4 70.1–87.4 76.9 74.6–79.0 70.6–81.0
Recent travel (% reporting having traveled in past 3 months)
All 32.5 30.0–35.1 26.7–39.9 20.1 18.1–22.3 10.7–29.8
6 months to 5 years 27.9 23.8–32.4 17.3–50.0 16.1 13.1–19.6 6.0–25.9
6–15 years 21.9 17.1–24.4 0–32.6 6.8 4.0–10.7 2.0–10.3
> 15 years 40.7 36.7–44.8 22.2–49.0 28.0 24.7–31.6 14.4–39.3
IRS = indoor residual spraying.
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(range = 24.7–97.0%) and 67.5% (range = 27.3–81.4%) of the
PCR-positive individuals had subpatent and asymptomatic infec-
tions, respectively; the majority was found in adults (P < 0.0001)
(Supplemental Table 2). Based on the clinical records, most
subpatent infections (83.8%; 95% CI = 79.6–87.5%) were not
provided treatment, whereas 95.1% (95% CI = 93.0–96.7%) of
RDT-positive individuals were prescribed an antimalarial drug.
Of all PCR-positive participants, 26.0% (range = 3.0–42.6%)
were patent and symptomatic; 21.1% (range = 0–32.7%) had
patent and asymptomatic infections, whereas 46.4% (range =
21.8–75.7%) were subpatent and asymptomatic for malaria.
In total, 6.5% (range = 3.0–21.2%) of PCR-positive individuals
were subpatent and symptomatic; 38.6% (17 of 44) of these
individuals were diagnosed with malaria, whereas 10 of 17 par-
ticipants as well as 27 participants not treated for malaria were
diagnosed with another fever-inducing illness, such as flu or
typhoid (Figure 2B).
Most infected individuals had one (43.2%) or two (29.4%)
allelic types, with the most diverse samples showing evidence
of seven different parasite clones. The FC27 subtype was most
prevalent, with 57 distinct allelic types identified compared
with 31 unique types from the 3D7 family. The MOI in the
study population was low, with a mean of 2.05 (95% CI =
1.92–2.19; range = 1.7–2.3) and 2.02 (95% CI = 1.91–2.15;
range = 1.5–2.3) clones per person in the first and second
surveys, respectively. Estimates of MOI were slightly higher
in the 6–15 years population, but no difference was observed
between patent and subpatent and symptomatic and asymp-
tomatic infections (Tables 3).
Factors associated with subpatent/asymptomatic infections.
In adjusted models, individuals > 15 years had 2.55 (95% CI =
1.50–4.30) times the odds of having an asymptomatic infec-
tion compared with those < 5 years. The odds of asymptom-
atic infections also being subpatent compared with patent
were 7.53 (95% CI = 4.88–11.62). If a person was attending
the health facility seeking care or sampled during the first
survey, they were more likely to be symptomatic (Table 4).
Similarly, those > 15 years had over three times the odds
of having a subpatent infection (odds ratio [OR] = 3.53; 95%
Figure 3. Comparison of health facility (HF) and community.
Comparison of transmission intensity estimates based on SCR from
HF and community surveys and the corresponding correlation coeffi-
cient (r). HF estimates were restricted to sampling that occurred in the
high-transmission season, and community estimates were restricted to
those residing in the health facility catchment area to minimize spatial
or seasonal biases as much as was possible.
Figure 2. Malaria results per facility. (A) Seroconversion rates per
health facility and transmission season (low [L] =October of 2011, high
[H] = July of 2012) for facilities sampled in both surveys. Note that
OmiroH and TalaH curves overlap. (B) PCR prevalence ordered
according to transmission intensity including subpatent and asymp-
tomatically infected individuals per health facility and transmission
season. Bars are stacked in the order of the legend, with negative on
the bottom and Asym/Sub on the top.
Table 3
Unadjusted MOI and range per facility, number of distinct alleles
(As), and allelic diversity (Rs) for PCR-positive samples (combined
results for both health facility surveys)
MOI 95% CI Range A Rs
Age
6 months to 5 years 1.98 1.85–2.13 1.46–2.36 70 67.59
6–15 years 2.23 2.03–2.46 1.75–2.45 67 67.0
> 15 years 1.97 1.84–2.13 1.39–2.5 58 56.77
Malaria drugs
No drug 2.02 1.93–2.13 1.56–2.31 80 47.45
ACT 2.02 1.74–2.42 1.33–2.5 37 36.39
Non-ACT 2.26 1.89–2.78 1.96–2.75 32 32.0
Detectable parasites
Patent 2.06 1.93–2.21 1.67–2.31 78 78.0
Subpatent 2.01 1.89–2.14 1.32–2.79 62 62.85
Symptoms
Symptomatic 2.03 1.92–2.16 1.40–2.34 78 76.14
Asymptomatic 2.03 1.89–2.18 1.52–2.51 62 62.0
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CI = 2.23–5.59) compared with the youngest age group, and
older children were one-half as likely to be asymptomatic
(OR = 0.54; 95% CI = 0.33–0.90). Those who had reported
taking antimalarial drugs in the past 2 weeks had greater odds
of having a subpatent infection: participants reporting having
taken non-artemesinin–based antimalarial drugs (i.e., quinine
or sulphadoxine-pyramethanime) had a 2.49 greater odds of
being subpatent (95% CI = 1.04–5.92), and those reported
having used artemesinin combination therapy (ACT) had
almost two times the odds of being subpatent, although this
finding was not significant (Table 5).
DISCUSSION
This study is one of the few studies and the first study in
Kenya to assess the use of surveys in health facilities as a means
of measuring malaria transmission intensity in an area where
transmission varies over a small geographical area.9,10,33 The
results of this study indicate that health facility-derived sero-
logical, parasitological, and molecular measures can detect dif-
ferences in transmission intensity at a small geographical scale
and are sensitive to seasonal changes. These findings suggest
that health facility surveys are able to provide a reasonable
measure of community-level transmission, are capable of delin-
eating areas of high or low malaria transmission and that the
use of serology and PCR added useful information to assess-
ment of transmission levels in the sampled populations that
would have been missed if sampling focused solely on those
cases suspected of having malaria.8,9,20
Similar to other studies, subpatent and asymptomatically
infections were detected in this setting. It is likely that over
one-half of malaria infections would have been missed had test-
ing been restricted to use of RDTs for symptomatic cases.11–13
The proportion of asymptomatic and subpatent infections dif-
fered by health facility, the main implication of which is that
variations in transmission intensity will affect the proportion of
infections missed using RDTs. The underestimation of malaria
burden can have significant implications for malaria surveillance
or development of control or elimination strategies based on
clinical data.16,30,34 For surveillance programs to capture the
complete burden of malaria in a region, the proportion of infec-
tions missed should be taken into account. More robust data
could be collected through use of more sensitive diagnostic
tools, such as PCR, or a high-quality surveillance system
targeting sentinel populations to get a more comprehensive
picture of malaria transmission.34–36 Alternatively, the limited
sensitivity of RDT/microscopy can be acknowledged and
adjusted for to estimate true prevalence or modify policy guide-
lines on an expectation of missed infections.11,37
Obtaining a better understanding of subpatent and asymp-
tomatic infections is key to identifying which individuals are
most likely to be missed by the current malaria surveillance
practices. Similar to other studies,14 our results suggest increased
odds of having subpatent and asymptomatic infections in older
age groups. These findings align with the current theory that,
in areas with stable transmission, older individuals will have
sufficient immunity to tolerate infections and maintain parasite
densities below the limit of detection of RDTs.30,38 Also,
reporting taking malaria drugs in the 2 weeks before the survey
was associated with having a subpatent malaria infection. The
increased odds of being subpatent in those reporting that they
took antimalarial drugs may be associated with residual
parasitemia shortly after treatment or the detection of DNA
from persisting gametocytes.39,40 An alternative explanation
for our finding is drug resistance: resistance to sulphadoxime-
pyrametamine is highly prevalent in western Kenya, and
although the use of this drug is officially limited to intermittent
treatment of pregnant women, it is widely available in most
private retailers.41,42 Another possible explanation includes sub-
optimal or self-dosing with malaria drugs. Compliance to drug
regimens in this area has not been studied to our knowledge, but
it is possible that, if people are not completing their regimen
properly, the drugs may only reduce parasite densities to
subpatent levels without completely clearing the infection.
Bias in recalling when or if they took that specific drug is also
a possibility.
We also explored the complexity of malaria infections to
gain additional insight into the molecular epidemiology of this
study population. MOI has been shown to be a marker of
transmission intensity that may have advantages in relatively
high-transmission settings, where parasite prevalence may
saturate.3 Although MOI has proven to be a useful metric of
malaria transmission intensity in certain settings,27,32 no sig-
nificant difference was found between facilities. This finding
may be because of the spatial overlap of the health facility
catchment areas, confounding factors not accounted for in the
unadjusted analysis, such as age, or the small sample sizes.
However, lower allelic diversities were observed in subpatent
and asympatomic infections as well as older individuals
and those who reported taking antimalarial drugs. The lower
allelic richness observed in facilities experiencing lower
Table 5
Unadjusted and adjusted results for fixed effects of mixed effects
logistic regression using health facility as random effect for variables
associated with having a subpatent malaria infection compared with
a patent infection
Outcome: subpatent infection
Unadjusted Adjusted
OR 95% CI OR 95% CI
Age category
6 months to 5 years 1.0 1.0 1.00 31.00
6–15 years 0.79 0.51–1.23 0.55 0.33–0.90
> 15 years 6.00 3.91–9.20 3.53 2.23–5.59
Asymptomatic 9.08 5.97–13.80 7.65 4.86–12.04
Antimalarial drug (2 weeks)
No drug 1.0 1.0 1.0 1.0
ACT 1.58 0.83–3.01 1.81 0.84–3.89
Non-ACT 1.64 0.81–3.29 2.49 1.04–5.92
Table 4
Unadjusted and adjusted results for fixed effects of mixed effects
logistic regression using health facility as random effect for variables
associated with having an asymptomatic malaria infection compared
with a symptomatic infection
Outcome: asymptomatic infection
Unadjusted Adjusted
OR 95% CI OR 95% CI
Study year 1.3 0.92–1.83 1.67 1.13–2.47
Age category
6 months to 5 years 1.00 1.00 1.00 1.00
6–15 years 1.64 1.09–2.47 1.98 1.26–3.11
> 15 years 6.14 3.89–9.71 2.55 1.50–4.30
Patient (versus
accompanying person)
0.11 0.05–0.25 0.26 0.10–0.67
Subpatent (versus patent) 8.64 5.81–12.83 7.53 4.88–11.62
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transmission intensity could be related to lower parasite den-
sities expected in these populations or could indicate that
certain low-density allelic forms were missed because of the
PCR process.
The study design had some important limitations. The intro-
duction of more sensitive diagnostic tools during the second
survey may have reduced the proportion of subpatent and
asymptomatic infections in that season. This was, however,
incorporated in the statistical analysis and had little impact on
the model results. Also, because of the cross-sectional nature of
this survey, misclassification of participants by asymptomatic/
subpatent status could have occurred.14 It is possible that some
individuals may have developed fever in subsequent days,
which may have impacted our estimates of asymptomatic
malaria. Similarly, the few studies that have looked at misclas-
sification of patent/subpatent over time suggest that a small
proportion of infections will shift between states, but the over-
all proportion detected does not shift dramatically, suggesting
that it is unlikely that following these individuals over time
would have a significant impact on these findings.28,43 Finally,
to obtain a specific understanding of how well health facilities
are able to gauge transmission intensity in the surrounding
community, health facility estimates need to be explicitly com-
pared with those of the community population that they are
supposed to represent. In this study, we have made use of an
existing community sample from the same area collected the
year before. Despite the temporal difference, the results indi-
cate a strong correlation in SCR between the convenience and
community sampling strategies, suggesting that the health facil-
ity provides a reasonable proxy for transmission intensity in the
surrounding community.
Ultimately, health facility surveys provide an attractive tool
to measure and detect heterogeneity in malaria transmission.
In terms of sampling, they include a broader sample of the
healthcare-seeking population instead of being restricted to
those suspected of having malaria, while at the same time,
they are more operationally attractive compared with com-
munity-based surveys in terms of the time and cost required
to collect samples.9,20 However, more work is required to
determine how these estimates compare with the surrounding
community. Estimates based on routinely used diagnostic
tools, such as RDTs, are likely to underestimate malaria prev-
alence because of the presence of subpatent and asymptom-
atic infections, but in our study, RDTs correctly identified
those health facilities with the highest transmission intensity
in their catchment area. More research is needed to further
explore the molecular epidemiology of malaria infections and
develop strategies that can easily identify these populations to
ensure that malaria control decisions are based on a complete
picture of malaria transmission.
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